Soft drugs based on hydrocortisone: The inactive metabolite approach and its application to steroidal antiinflammatory agents

Pharmaceutical Research

Volumn 16, Issue 6, 1999, Pages 961-967

  Little, Roy J ^a   Bodor, Nicholas ^b   Loftsson, Thorsteinn ^c  

^a UNIVERSIDAD DE LOS ANDES   (Venezuela)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF ICELAND   (Iceland)

Author keywords

Antiinflammatory steroids; Drug design; Soft drugs; Structure activity relations

Indexed keywords

ANTIINFLAMMATORY AGENT; GLYCOGEN; HYDROCORTISONE DERIVATIVE; HYDROCORTISONE VALERATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG HYDROLYSIS; DRUG STABILITY; DRUG SYNTHESIS; GLYCOGEN LIVER LEVEL; GRANULOMA; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PALLOR; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION; THYMUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CULTURE MEDIA; GRANULOMA; HYDROCORTISONE; HYDROLYSIS; INJECTIONS, INTRAPERITONEAL; MALE; NEOPLASM TRANSPLANTATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032982918     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018907026460     Document Type: Article

References (30)

1. 1. N. Bodor. Novel approaches to the design of safer drugs: Soft drugs and site-specific chemical delivery systems. Adv. Drug Res. 13:255-331 (1984).
2. 2. N. Bodor, K. B. Sloan, R. J. Little, S. H. Selk, and L. Caldwell. Soft Drugs IV. 3-Spirothiazolidines of hydrocortisone and its derivatives. Int. J. Pharm. 10:307-321 (1982).
3. 1, 9α-fluorohydrocortisone (Aristocort) and related steroids. J. Pharmacol. Exp. Ther. 122:60A (1958).
4. 4. G. J. Blackwell, R. Carnuccio, M. Di Rosa, R. J. Flower, L. Parente, and P. Persico. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature (London) 287:147-149 (1980).
5. 5. E. J. Ariëns. Modulation of Pharmacokinetics by Molecular Manipulation. Drug Design, vol II, Chapt. 1.
6. 6. M. Scott, L. A. Malmsten, and I. Thelin. Effect on plasma cortisol level and urinary cortisol excretion, in healthy volunteers, after application of three different topical steroid ointments under occlusion. Acta Derm.-Venereol. 61:543-6 (1981).
7. 7. C. Monder and H. L. Bradlow. Cortoic acids: explorations at the frontier of corticosteroid metabolism. Recent Prog. Horm. Res. 36:345-400 (1980).
8. 8. T. Loftsson and N. Bodor. Improved delivery through biological membranes X: Percutaneous absorption and metabolism of methylsulfinyl 2-acetoxybenzoate and related aspirin prodrugs. J. Pharm. Sci. 70:756-758 (1981).
9. 9. W. J. Wheeler, W. E. Wright, V. D. Line, and J. A. Frogge. Orally active esters of cephalosporin antibiotics. Synthesis and biological properties of 7-(D 2-amino-2-phenylacetamido)-3-[5-methyl-(1,3, 4-thiadiazol-2-yI) thiomethyl]-3-cephem-4-carboxylic acid. J. Med. Chem. 20:1159-1164 (1977).
10. 10. N. Bodor and J. J. Kaminski. Soft Drugs. 2. Soft alkylating compounds as potential antitumor agents. J. Med. Chem. 23:566-569 (1980).
11. 11. H. Laurent, E. Gerhards, and R. Wiechert. Synthesis of novel antiinflammatory steroids. Angew. Chem., Int. Ed. Engl. 14:65-69 (1975).
12. 12. W. Mützel. Pharmakokinetik und biotransformation von fluocortin-butylester beim menschen. Arzneim. Forsch. 27:2230-2233 (1977).
13. 13. G. H. Phillipps. Locally active corticosteroids: structure-activity relationships. In L. Wilson, R Marks (eds.), Mech. Top. Corticosteroid Act., Glaxo Symp., 1974, Churchill-Livingstone, London, 1976, pp. 1-18.
14. 14. D. J. Kertesz and M. Marx. Thiol esters from steroid 17α-carboxylic acids: carboxylate activation and internal participation by 17α-acylates. J. Org. Chem. 51:2315-2328 (1986).
15. 15. R. J. Little. Design and synthesis of several antiinflammatory soft steroids and analysis of factors involved in the biological activities thereof. Ph.D. Thesis. University of Florida, 1983.
16. 16. S. M. McElvain and J. T. Venerable. Ketene Acetals. XXI. The Dealcoholation of Orthoesters. Dimethylketene Dimethyl Acetal. J. Am. Chem. Soc. 72:1661-1669 (1950).
17. 17. S. Miyano and H. Hashimoto. A convenient synthesis of chloroiodomethane from dichloromethane and sodium iodide in dimethylformamide. Bull. Chem. Soc. Jpn. 44:2864 (1971).
18. 18. R. Gardi, R. Vitali, G. Vitali, and A. Ercoli. Antiinflammatory activities of 17,21-methyl ortho esters, 17-mono-and 17,21-diesters of 6α, 9α-difluorocorticosteroids. J. Med. Chem. 15:556-558 (1972).
19. 19. R. Gardi, R. Vitali, and A. Ercoli. Preparation and reaction of 17-mono esters. Gazz. Chim. Ital. 93:431-450 (1963).
20. 5 gruppe. Helv. Chim. Acta 25:988-1022 (1942).
21. 21. P. Druzgala and N. Bodor. O-Alkylation of cortienic acid and synthesis of a new class of glucocorticoid containing a 17α-alkoxy, a 17α (1′-alkoxyethyloxy), a 17α-alkoxymethyloxy, or a 17α-methylthiomethyloxy function. Steroids 56:490-494 (1991).
22. 22. B. W. Barry and R. Woodford. Activity and bioavailability of topical steroids: In vivo-in vitro correlations for the vasoconstrictor test. J. Clin. Pharm. 3:43-65 (1978).
23. 1-fluorohydrocortisone. Proc. Soc. Exp. Biol. Med. 89:371 (1955).
24. 24. N. R. Stephenson. The effect of corticosteroid analogues on the thymus gland of the immature rat. J. Pharm. Pharmacol. 12:411-415 (1960).
25. 25. R. Meier, W. Schuler, and P. Desaulles. Zur frage der mechanismus der hemmung des bindegewebswachstums durch cortisone. Experentia 6:469-471 (1950).
26. 26. N. Bodor, T. Loftsson, and W.-M. Wu. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, Loteprednol Etabonate. Pharm. Res. 9:1275-1278 (1992).
27. 27. G. Hochhaus, L.-S. Chen, A. Ratka, P. Druzgala, J. Howes, N. Bodor, and H. Derendorf. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug, Loteprednol Etabonate in rats and dogs. J. Pharm. Sci. 81:1210-1215 (1992).
28. 28. K. B. Sloan and J. H. Perrin. Comments concerning 'Pharmacokinetic characterization and tissue distrubution of the new glucocorticoid soft drug, Loteprednol Etabonate in rats and dogs.' J. Pharm. Sci. 83:1066 (1994).
29. 29. G. Hochhaus, P. Druzgala, J. F. Howes, N. Bodor, and H. Derendorf. Response to the commentary on 'Pharmacokinetic characterization and tissue distrubution of the new glucocorticoid soft drug, Loteprednol Etabonate in rats and dogs.' J. Pharm. Sci. 83:1067 (1994).
30. 30. H. Schmidli. Multivariate prediction for QSAR. Chemom. Intell. Lab. Syst. 37:125-134 (1997).